PubMed دسترسی آزاد

Hypersensitivity reactions to dengue vaccine TAK-003 (Qdenga®) following an immunization campaign targeting children and adolescents.

Márcia Paulliny Soares Bahia, Silon de Souza Gomes Junior, Argus Leão Araújo, Hoberdan Oliveira Pereira, José Geraldo Leite Ribeiro, Alexandre Sampaio Moura• 2026• Revista da Sociedade Brasileira de Medicina Tropical

استودیوی صوتی مقاله

پخش حرفه‌ای فارسی و انگلیسی

در حال بررسی نسخه‌های صوتی ذخیره‌شده…

صوت تولیدشده با هوش مصنوعی است. برای کاربرد علمی یا درمانی، متن و منبع اصلی را بررسی کنید.

خواندن هوشمند فارسی و انگلیسی در حال آماده‌سازی صداهای مرورگر…

تنظیم صدای طبیعی و سرعت

صدای فارسی صدای انگلیسی سرعت خواندن

صداهایی که در نامشان «Natural»، «Neural» یا «Online» دیده می‌شود معمولاً طبیعی‌ترند. انتخاب صدا به صداهای نصب‌شده در ویندوز و مرورگر شما بستگی دارد.

چکیده اصلی

BACKGROUND: A national dengue vaccination campaign using TAK-003 was launched in 2024, targeting adolescents. Post-licensure surveillance suggested higher-than-expected hypersensitivity reactions. METHODS: We conducted a descriptive study using vaccine adverse event data and vaccination records from Belo Horizonte among individuals aged 6-14 years. RESULTS: Of the 146,115 doses administered, 28 hypersensitivity reactions were reported (191.6 per million), including nine cases of anaphylaxis and two of anaphylactic shock. All events followed the first dose. Mean age was 9.4 years, and mean time to symptom onset was 31 minutes. CONCLUSIONS: Hypersensitivity rates exceeded expected vaccine-associated levels, reinforcing the need for continued pharmacovigilance.

متن کامل اصلی

نسخه دارای مجوز در منبع علمی در دسترس است.

لینک مستقیم از metadata منبع گرفته شده و در تب جدید باز می‌شود.

باز کردن متن کامل

در همین زیرشاخه

مقاله‌های مرتبط

PubMed2026

Flibanserin safety in real-world use: a decade of US Food and Drug Administration Adverse Event Reporting System pharmacovigilance evidence.

BACKGROUND: Flibanserin, a centrally acting 5-HT1A agonist and 5-HT2A antagonist, is the first approved therapy for acquired, generalized hypoactive sexual desire disorder in premenopausal women. Despite its clinical availability, post-marketing data on real-world safety remain limited. METHODS: A retrospective pharmacovigilance analysis was conducted using the US Food and Drug Administration Adverse Event Reporting System from 2016 to…

PubMed2026

Risk of Major Malformations Following First-Trimester Exposure to Cariprazine: Preliminary Data From the MGH National Pregnancy Registry for Psychiatric Medications.

OBJECTIVE: Systematically collected pregnancy safety data for cariprazine have been lacking, despite growing use of this medication across psychiatric indications. The goal of this analysis was to determine the risk of major malformations among infants of mothers with psychiatric illness who used cariprazine during the first trimester of pregnancy compared to unexposed controls. METHODS: The National Pregnancy Registry for Psychiatric …

PubMed2026

Using Pharmacovigilance Data for Signal Detection of Drug Interactions for Rosuvastatin.

The 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitor rosuvastatin is a substrate of breast cancer resistance protein (BCRP). BCRP inhibition increases rosuvastatin plasma concentrations and may result in concentration-dependent muscle toxicity, at worst rhabdomyolysis. We investigated if concomitant use of rosuvastatin and drugs identified as in vitro BCRP inhibitors shows an increased number of rhabdomyolysis events based on…

PubMed2026

Assessing the risk of cataracts associated with medications: A pharmacovigilance analysis of the FAERS database.

Cataracts are a leading cause of global blindness and visual impairment, with drug-induced cataracts emerging as a significant yet understudied contributor. This study aimed to comprehensively and systematically investigate medication-related cataract risk signals using data from the FDA Adverse Event Reporting System. We searched the FDA Adverse Event Reporting System database for all reported cases of medication-related cataracts fro…